Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 11:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: bupropion XL Clear all
Completed Phase 4 Interventional Results available

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00404755
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia
Interventions
escitalopram, bupropion, imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 1 Interventional

The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity

NCT00205946
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Bupropion, Placebo
Drug
Lead sponsor
Affective Neuroscience Laboratory
Other
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 4 Interventional

Wellbutrin XL Effects on SSRIs Induced Changes

NCT00456820
View directory record Official record
Conditions
Depression, Side Effects, Sexual Dysfunction, Apathy
Interventions
Wellbutrin XL
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 15, 2007 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 2Phase 3 Interventional

Female Orgasmic Disorder (FOD) and Wellbutrin XL

NCT00248209
View directory record Official record
Conditions
Orgasmic Disorder
Interventions
Wellbutrin XL
Drug
Lead sponsor
Segraves, R., T., M.D., Ph.D.
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 4 Interventional

Treatment of Depression Following Multiple Brain Tests

NCT00296777
View directory record Official record
Conditions
Major Depression, Dysthymia
Interventions
Escitalopram, Bupropion, Imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM

NCT00318409
View directory record Official record
Conditions
Substance Abuse, HIV Infections
Interventions
Bupropion, Placebo
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

An Open Label Trial of Bupropion and Naltrexone for Binge Drinking

NCT02842073
View directory record Official record
Conditions
Binge Drinking
Interventions
Naltrexone, Bupropion
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 34 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

Smoking-Cessation and Stimulant Treatment (S-CAST)

NCT01077024
View directory record Official record
Conditions
Cocaine Dependence, Methamphetamine Dependence, Nicotine Dependence
Interventions
Smoking-cessation treatment
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Tucson, Arizona • Rancho Cucamonga, California • Tarzana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 19, 2026, 11:45 AM EDT
Not listed Phase 2 Interventional

Lamotrigine and Bupropion for Meniere's Disease

NCT05420350
View directory record Official record
Conditions
Meniere Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
Interventions
Lamotrigine and Bupropion, Placebo
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 19, 2026, 11:45 AM EDT
Terminated Phase 4 Interventional Results available

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

NCT00429169
View directory record Official record
Conditions
Depression
Interventions
Paroxetine, Bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery

NCT02173886
View directory record Official record
Conditions
Roux en Y Gastric Bypass
Interventions
Bupropion SR and XL
Drug
Lead sponsor
North Dakota State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 4 Interventional

Sexual Functioning Study With Antidepressants

NCT00316160
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
45
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 19, 2026, 11:45 AM EDT
Terminated Phase 4 Interventional Results available

Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

NCT03993457
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Bupropion
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NCT03180294
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Bupropion 150 mg XL, Placebo
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
362
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 262 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions

NCT00865462
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2010 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

NCT04352101
View directory record Official record
Conditions
Major Depression
Interventions
Bupropion XL, Escitalopram
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 4 Interventional

Wellbutrin XL, Major Depressive Disorder and Breast Cancer

NCT00234195
View directory record Official record
Conditions
Breast Cancer, Major Depressive Disorder
Interventions
bupropion extended release (Wellbutrin XL)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2007 · Synced Sep 19, 2026, 11:45 AM EDT
Recruiting Phase 4 Interventional

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

NCT04604509
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

Connectivity Affecting the Antidepressant REsponse Study

NCT02332291
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Bupropion XL
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 19, 2026, 11:45 AM EDT
Active, not recruiting Phase 3 Interventional

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799
View directory record Official record
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

NCT00863941
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2010 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study

NCT01748955
View directory record Official record
Conditions
Depression, Suicidal Ideation
Interventions
Paroxetine CR for Major Depressive Episode, Bupropion XL for Major Depressive Episode
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

NCT00439868
View directory record Official record
Conditions
Depressive Disorder
Interventions
WellbutrinXL, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 19, 2026, 11:45 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence

NCT02111798
View directory record Official record
Conditions
Substance Abuse, Cocaine Dependence
Interventions
Placebo, Bupropion XL, Abstinence Initiation, Relapse Prevention
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 19, 2026, 11:45 AM EDT